Literature DB >> 3159804

Pathogenesis of graft-versus-host reactions (GVHR) and GVH-like diseases.

E Gleichmann, H Gleichmann.   

Abstract

The graft-versus-host reaction (GVHR) in both mice and humans can lead to the development of a broad spectrum of clinical and pathological symptoms. These symptoms are strikingly similar to those of a number of diseases of proven or presumed immunological origin, such as systemic lupus erythematosus (SLE), other collagen vascular diseases, lymphoproliferative disease, and aplastic anemia. The purpose of our investigation was to describe the immunological and pathological events that take place in the course of graft-versus-host disease (GVHD) and to gain insight into the cellular mechanisms underlying these events. To this end, a model was employed in which nonirradiated F1 mice were used as recipients of parental lymphoid cells. By pathological manifestations, 2 basic forms of GVHD can be distinguished in such non-irradiated F1 recipients: One is acute GVHD which is often lethal. It is characterized by a variety of suppressive (hypoplastic) pathological symptoms, including a severe hypoplasia of the lymphohemopoietic system accompanied by aplastic anemia and hypogammaglobulinemia. The other basic form is characterized by stimulatory symptoms, such as persistent lymphoid hyperplasia, formation of autoantibodies, and development of pathological symptoms reminiscent of SLE and other collagen vascular diseases. The suppressive pathological graft-versus-host (GVH) symptoms are caused by T suppressor/killer (TS/K) cells of the donor which react towards allogeneic class-I-structures of the F1 recipient's major histocompatibility complex (MHC). The stimulatory pathological GVH symptoms, by contrast, are caused by donor T helper (TH) cells which react toward the recipient's allogeneic class-II-MHC structures. The possible implications of these observations for the pathogenesis of a number of GVH-like diseases in humans are discussed. The hypothesis is advanced that some of these GVH-like conditions, which arise either e causa ignota or after exposure to certain viruses or drugs, are caused by T lymphocytes reacting against self-MHC structures on lymphohemopoietic cells that were rendered "foreign". By analogy to GVHD, it is conceivable that the development of either stimulatory or suppressive GVH-like symptoms in individuals exposed to a given virus or sensitizing drug depends not on the etiologic agent per se, but on whether the predominant response is made by the individual's TH or TS@K cells. This, in turn, might depend on whether the agent becomes immunogenic in combination with class-II or class-I alloantigens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159804     DOI: 10.1111/1523-1747.ep12275619

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  17 in total

1.  Donor CD8 T cell activation is critical for greater renal disease severity in female chronic graft-vs.-host mice and is associated with increased splenic ICOS(hi) host CD4 T cells and IL-21 expression.

Authors:  Anthony D Foster; Mark Haas; Irina Puliaeva; Kateryna Soloviova; Roman Puliaev; Charles S Via
Journal:  Clin Immunol       Date:  2010-05-06       Impact factor: 3.969

Review 2.  Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE.

Authors:  I Puliaeva; R Puliaev; C S Via
Journal:  Autoimmun Rev       Date:  2008-08-24       Impact factor: 9.754

Review 3.  Treatment of lichen planus.

Authors:  G F Oliver; R K Winkelmann
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 4.  Graft versus leukemia in bone marrow transplantation.

Authors:  M Boranić
Journal:  Blut       Date:  1988-08

Review 5.  Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens.

Authors:  Charles S Via
Journal:  Curr Opin Rheumatol       Date:  2010-09       Impact factor: 5.006

Review 6.  Advances in lupus stemming from the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Trends Immunol       Date:  2010-03-31       Impact factor: 16.687

7.  Pre-clinical screening of immunomodulatory compounds using the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Clin Immunol       Date:  2011-06-12       Impact factor: 3.969

8.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

9.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Intrinsic Differences in Donor CD4 T Cell IL-2 Production Influence Severity of Parent-into-F1 Murine Lupus by Skewing the Immune Response Either toward Help for B Cells and a Sustained Autoantibody Response or toward Help for CD8 T Cells and a Downregulatory Th1 Response.

Authors:  Kateryna Soloviova; Maksym Puliaiev; Mark Haas; Clifton L Dalgard; Brian C Schaefer; Charles S Via
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.